The pharmaceutical company Indivior Solutions Inc. pleaded guilty July 24 to a federal false statements charge and agreed with its parent companies Indivior Inc. and Indivior P.L.C. to pay $600 million to resolve criminal and civil liability related to the marketing of Suboxone, a drug approved by the FDA in 2002 for use as a treatment for opioid addiction. Together with a 20... Read More